NCT06126172Active, not recruiting
Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions
Source: ClinicalTrials.gov · Last updated 20 Mar 2026
Brief summary (registry, in English)
Prostate cancers (PCA) are a heterogeneous group which include indolent tumors that has no clinical significance to very aggressive cancer that could result in morbidities and mortality. Thus, an accurate risk stratification at the time of PCA diagnosis is crucial. The histological examination of PCA biopsy specimens could not accurately predict the final tumor aggressiveness shown on radical prostatectomy specimens because of heterogeneous distributions of the most malignant tumor cells. Prostate multiparametric magnetic resonance imaging (mpMRI) has been generally accepted to be the best imaging modality for detecting and localizing prostate cancers themselves. Furthermore, the rapid development of radiomics provide comprehensive quantitative information of all tumor data which could be used for risk stratification and prognosis prediction. Thus, this study plans to enroll 200 eligible patients who undergo prostate mpMRI first, followed by radical prostatectomy for prostate cancers. We use radiomics extracted from prostate mpMRI for risk stratification patients of histological aggressiveness as well as to predict very early recurrence of PCA patients within 6 months after radical prostatectomy.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 125 (estimated)
- First submitted
- 6 Nov 2023
- Start date
- 15 Feb 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Chang Gung Memorial Hospital
- Diseases
- Prostate cancer
- NCT number
- NCT06126172
What you commit to
- Study type: Interventional
- Planned participants: 125
- From 15 Feb 2022 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Without pathological examination confirmed prostate cancer.
Other
- mpMRI photography not completed.
- mpMRI images are damaged or poor in quality and cannot be interpreted.
- Patient withdraw informed consent.
Who the study is looking for
- Aged over 20 years old.
- Suspected or confirmed prostate cancer.
- Undergoing prostate mpMRI before clinical treatment.
- Normal renal function(i.e.: estimated GFR ≧60).
- No allergy history to gadolinium based contrast agent.
- Agree to participate this study and sign informed consent.
Age in the registry: 20 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Li-Jen Wang Coordinator of this site? Confirm its status | Taoyuan | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.